Filing Impact
Filing Sentiment
Form Type
144
Takeda Pharm
Jul 30, 2025
Takeda Announces First-Quarter FY2025 Results With Significant Late-Stage Pipeline Progression
Jul 21, 2025
Takeda Receives FDA 510(k) Clearance for HyHubTM and HyHubTM Duo Devices to Simplify HYQVIA® Administration
Jul 14, 2025
Takeda Announces Positive Results from Two Pivotal Phase 3 Studies of Oveporexton (TAK-861) in Narcolepsy Type 1
Jun 25, 2025
Takeda Announces New Assignments of Directors